DUSP6 and melanoma: To further explore the role and potential targeting of DUSP6-mediated negative regulatory signaling from the MAPkinase pathway to p53 in melanoma cells, we used a selective small molecule inhibitor of DUSP6, 2-benzylidene-3-(cyclohexylamino)-1-indanone hydrochloride (BCI) which inhibits DUSP6 allosterically [28,29].